Associated Papers
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network.
Gaggiano C et al.
Therapeutic Advances in Musculoskeletal Disease, 2021
Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide.
Soriano A et al.
Frontiers in Immunology, 2020
Tumor necrosis factor receptor-associated periodic syndrome: toward a molecular understanding of the systemic autoinflammatory diseases.
Ryan JG et al.
Arthritis and Rheumatism, 2009
Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome.
Gattorno M et al.
Arthritis and Rheumatism, 2008
TNF-receptor-associated periodic syndrome (TRAPS): an autosomal dominant multisystem disorder.
Rezaei N
Clinical Rheumatology, 2006
The tumour necrosis factor receptor-associated periodic syndrome: current concepts.
Stojanov S et al.
Expert Reviews in Molecular Medicine, 2005
Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease.
Amoura Z et al.
Arthritis and Rheumatism, 2005
Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness--the ECTIM, AXA, EVA and GENIC Studies.
Poirier O et al.
European Journal of Human Genetics : Ejhg, 2004
The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.
Hull KM et al.
Medicine, 2002
Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature.
Cantarini L et al.
International Journal of Immunopathology and Pharmacology, 0
Select a paper to view details